Discover 156 paid clinical trials in Fayetteville, Arkansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 156
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
for
Schizophrenia
Location: Rogers AR, Little Rock AR, Richardson TX, DeSoto TX,
Sponsor: MapLight Therapeutics
Sex: All
Age: 18 - 65
Code: NCT07459647
Phase 2, Recruiting
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
for
Major Depressive Disorder (MDD)
Location: Rogers AR, Oklahoma City OK, O'Fallon MO,
Sponsor: Supernus Pharmaceuticals, Inc.
Sex: All
Age: 18 - 70
Code: NCT07226661
Phase 2, Recruiting
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Location: Springdale AR, Margate FL, Miami FL, Montreal
Sponsor: AstraZeneca
Sex: Male
Age: 18+
Code: NCT07711002
Phase 3, Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
for
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Location: Rogers AR, Little Rock AR, Richardson TX, St Louis MO,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18 - 65
Code: NCT06951711
Phase 3, Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
for
Non-Small Cell Lung Cancer
Location: Springdale AR, Little Rock AR, Kansas City MO,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06357533
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
for
Breast Cancer
Location: Springdale AR, St Louis MO, Dallas TX, Des Moines IA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06103864
Phase 3, Recruiting
BostonGene and Exigent Genomic INsight Study
for
Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
Location: Rogers AR, Plano TX, St Louis MO, Stephenville TX,
Sponsor: Alto Neuroscience
Sex: All
Age: 18 - 70
Code: NCT05922878
Phase 2, Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Fort Smith AR, Little Rock AR, Jonesboro AR, Olathe KS,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06058377
Phase 3, Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
for
Fallopian Tube Endometrioid Adenocarcinoma,
Location: Fort Smith AR, Branson MO, Joplin MO, Springfield MO,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06580314
Phase 3, Recruiting
GEMINI-NSCLC: NSCLC Biomarker Study
for
Non-Small Cell Lung Cancer
Location: Fort Smith AR, Joplin MO, Springfield MO, Tulsa OK,
Sponsor: Tempus AI
Sex: All
Age: 18+
Code: NCT05236114
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
for
Pancreatic Cancer, Metastatic Pancreatic Cancer,
Location: Fort Smith AR, Springfield MO, Oklahoma City OK,